107 related articles for article (PubMed ID: 24237017)
1. Devising a patent strategy to protect the IP of biologics in light of ambiguities, loopholes and pitfalls in the regulatory scheme.
Hsing BC; Palla SW
Pharm Pat Anal; 2013 Mar; 2(2):153-5. PubMed ID: 24237017
[No Abstract] [Full Text] [Related]
2. Strategic considerations under the Biologics Price Competition and Innovation Act.
Marquardt JL; Auten SR
Expert Opin Ther Pat; 2013 Aug; 23(8):915-8. PubMed ID: 23829693
[TBL] [Abstract][Full Text] [Related]
3. U.S. patent law. Case probes what's fair game in the search for new drugs.
Kintisch E
Science; 2005 Apr; 308(5719):174. PubMed ID: 15821048
[No Abstract] [Full Text] [Related]
4. Of patents and patent disputes: The TNFα patent files. Part 1: Humira.
Storz U
Hum Antibodies; 2017; 25(1-2):1-16. PubMed ID: 27792008
[TBL] [Abstract][Full Text] [Related]
5. Biologics and biosimilars: a legal perspective from Canada.
Furlanetto A; Purcell N
Pharm Pat Anal; 2016; 5(2):79-81. PubMed ID: 26891094
[No Abstract] [Full Text] [Related]
6. Unfair competition under the TRIPS agreement: protection of data submitted for the registration of pharmaceuticals.
Correa CM
Chic J Int Law; 2002; 3(1):69-85. PubMed ID: 15709300
[No Abstract] [Full Text] [Related]
7. Favourable changes to the IP and tax systems in the UK for drug development.
Watson R
Expert Opin Ther Pat; 2013 Jul; 23(7):773-5. PubMed ID: 23713616
[TBL] [Abstract][Full Text] [Related]
8. Ownership of knowledge--the role of patents in pharmaceutical R&D.
Correa CM
Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
[TBL] [Abstract][Full Text] [Related]
9. Clarification: 510k is premarket notification; it provides no patent or FDA approval.
Burkhart CG
J Drugs Dermatol; 2008 Feb; 7(2):105. PubMed ID: 18335644
[No Abstract] [Full Text] [Related]
10. Patent watch: post-approval testing shielded from patent infringement.
Harrison C
Nat Rev Drug Discov; 2012 Sep; 11(9):666. PubMed ID: 23097768
[No Abstract] [Full Text] [Related]
11. Staving off death: a case study of the pharmaceutical industry's strategies to protect blockbuster franchises.
Gorlin DI
Food Drug Law J; 2008; 63(4):823-64. PubMed ID: 19601385
[No Abstract] [Full Text] [Related]
12. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
Dinh TQ
Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
[No Abstract] [Full Text] [Related]
13. Realizing two-tiered innovation policy through drug regulation.
Ridgway WE
Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
[No Abstract] [Full Text] [Related]
14. Market exclusivity for biologics.
Wheadon DE
N Engl J Med; 2010 Feb; 362(7):661; author reply 661-2. PubMed ID: 20164494
[No Abstract] [Full Text] [Related]
15. EU court gets tough on patent extensions for combo products.
Waters H
Nat Med; 2012 Jan; 18(1):4. PubMed ID: 22227647
[No Abstract] [Full Text] [Related]
16. The application of the patent laws to the drug approval process.
Coggio BD; Cerrito FD
Food Drug Law J; 1997; 52(4):345-55. PubMed ID: 10346669
[No Abstract] [Full Text] [Related]
17. The new follow-on-biologics law: a section by section analysis of the patent litigation provisions in the Biologics Price Competition and Innovation Act of 2009.
Dougherty MP
Food Drug Law J; 2010; 65(2):231-45, i. PubMed ID: 24475541
[TBL] [Abstract][Full Text] [Related]
18. [Patent law: avoiding pitfalls].
Kruspig RA
Chirurg; 2006 Nov; Suppl():354-5. PubMed ID: 17598272
[No Abstract] [Full Text] [Related]
19. SuperGenerics: a better alternative for biogenerics.
Charles SA
Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591
[No Abstract] [Full Text] [Related]
20. Where have all the antibiotic patents gone?
Katz ML; Mueller LV; Polyakov M; Weinstock SF
Nat Biotechnol; 2006 Dec; 24(12):1529-31. PubMed ID: 17160057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
